ResveratrolConsumer
avert online
consumer fraud
ResveratrolQuiz
test your knowledge
New E-Book
How the world got lost on
the road to an anti-aging pill
Subscribe to our newsletter to receive email notifications when new articles are posted.
October 7, 2010: by Bill Sardi
Las Vegas, NV (October 7, 2010) – Longevinex® is the first resveratrol-based nutriceutical to demonstrate it abolishes the earliest sign of blood vessel aging and significantly inhibits a marker of inflammation, in humans.
In a 3-month study conducted among patients with metabolic syndrome (obesity, elevated blood sugar) in Japan, researchers report that 1-capsule of Longevinex® taken daily strongly inhibits loss of “flow mediated dilatation,” which is described as impaired ability of arteries to widen (dilate) with increased heart rate induced by physical exertion or stress. If the arteries do not dilate when a human goes from a resting heart rate to a faster heart rate, then the artery remains abnormally narrow, blood pressure rises abnormally, and the threat of a stroke becomes real.
In addition to flow-mediated dilatation, Longevinex® significantly lowered insulin, insulin resistance, adiponectin (a protein secreted by fat cells) and C-reactive protein (a marker of inflammation). Longevinex®, which provides a unique blend of resveratrol, quercetin, ferulic acid, rice bran IP6 from botanical sources as well as vitamin D3, was given to 15 patients and compared to conventional care. There were no statistically significant improvements noted in the patients receiving conventional doctor’s care.
Bill Sardi, spokesperson for Longevinex®, says this very encouraging news since it begins to answer the demand for human studies, as up to this point in time most of the resveratrol research has been done in lab dishes or the animal laboratory. This study also encouragingly points to markers linked with mortality which show resveratrol may one day live up to its billing as an anti-aging pill.
Results of the study will be presented at an upcoming meeting of the Japanese Circulation Society.
A chart providing the full results of the study is presented below. ### © 2010 Resveratrol Partners LLC
| Comparison of 1-Capsule/Day Longevinex® Vs. Conventional Care Among Human Subjects With Metabolic Syndrome Obesity, Elevated Blood Sugar) | ||||||
| Longevinex Group (15 subjects) | Conventional Care Group (15 subjects) | |||||
| Measured Parameters – 3 month study | Before | After | P value | Before | After | P value |
| Body mass index (weight + height to indicate %body fat) | 28.4 | 28.2 | 0.202 null | 26.2 | 25.8 | 0.255 null |
| Waist circumference (in centimeters; 2.5 centimeters = 1 inch) | 100 | 99 | 0.524 null | 92.4 | 92.5 | 0.784 null |
| Body weight (in kilograms; 1 kilogram = 2.2 lbs) | 77 | 76 | 0.266 null | 68 | 67 | 0.254 null |
| Systolic blood pressure (thrusting pressure) (mmHg) | 131 | 126 | 0.398 null | 129 | 131 | 0.487 null |
| Diastolic blood pressure (resting pressure) (mmHg) | 73 | 76 | 0.456 null | 77 | 75 | 0.454 null |
| Triglycerides (mg/dl) | 138 | 133 | 0.741 null | 116 | 116 | 0.963 null |
| High-density lipoprotein (HDL “good” cholesterol) (mg/dl) | 47 | 46 | 0.693 null | 51 | 50 | 0.485 null |
| Low-deinsity lipoprotein (LDL “bad” cholesterol) (mg/dl) | 100 | 99 | 0.700 null | 112 | 106 | 0.207 null |
| Ferririn (iron storage protein; 20-50 is healthy range) (ng/ml) | 128 | 127 | 0.881 null | 128 | 121 | 0.372 null |
| Hemoglobin A1c (long-term blood sugar control) (%) | 5.4 | 5.3 | 0.589 null | 5.8 | 5.8 | 0.919 null |
| Fasting blood sugar (mg/dl) | 106 | 107 | 0.882 null | 105 | 112 | 0.087 null |
| Fasting serum insulin (µg/ml) | 14.7 | 9.3 | 0.021* | 13.7 | 16.7 | 0.289 null |
| Homeostasis model for insulin resistance | 14.7 | 9.3 | 0.026* | 13.7 | 16.4 | 0.289 null |
| Total adiponectin (protein secreted by fat cells) (µg/ml) | 6.43 | 7.42 | 0.052* | 7.31 | 6.63 | 0.186 null |
| High molecular weight adiponectin (µg/ml) | 3.12 | 3.75 | 0.030* | 0.356 | 0.332 | 0.453 null |
| Highly-sensitive C-reactive protein (inflammation) (mg/dl) | 0.151 | 0.068 | 0.024* | 0.175 | 0.105 | 0.246 null |
| Nitrate + nitrite (marker for nitric oxide) (µmol/L) | 47.9 | 65.1 | 0.025* | 44.7 | 45.4 | 0.740 null |
| Flow-mediated dilatation (widening of arteries upon exertion) | 6.2% | 9.0.% | 0.007* | 6.0% | 6.5% | 0.227 null |
| Legend:
P value = statistical significance (lower number is greater significance, example: 0.007 is better than 0.020; 0.050 and lower is better than chance); *statistically significant Data and chart: ©2010 Resveratrol Partners LLC www.longevinex.com |
||||||
Posted in Resveratrol
Add comments »
Sir,
Thank you for your continued efforts in eliciting human studies of the nutriceutical Longevinex. Particularly noteworthy were the C-reactive protein results. Are there any other study or literature on this particular point ?
A well designed and composed neutriceutical offers the advantage of low toxicity and low side effect. Whereas a pharmaceutical may exhitbit profound toxicity or side effects which we tolerate in the hope of a cure from a specific disease.
Wholesomeness and life quality improvement are of greater interest than longevity. The two may go hand in hand in a way.
ResveratrolNews.com:
We find there is a continuum of dose that ranges from ineffective, to efficacy, to counter-effectiveness. This is known as the U-shaped or J-shaped risk curve. Mortality risk drops with modest use, but rises with over-consumption. For wine drinkers, consumption of 3-5 glasses of red wine dramatically reduces mortality risk, particularly due to heart problems, but more than 5 glasses increases risk for death. That much wine is quite inebriating, but provides about 180-300 milligrams of wine solids called polyphenols. The idea of a well-designed red wine pill is to mimic the same effect without the alcohol. It would appear, from population studies, particularly among the long-living French, that just 180-300 milligrams of a mixture of small molecules (resveratrol, quercetin, catechin, ferulic acid, malvidin, kaempferol, gallic acid, typically found in red wine) produces a more profound effect than higher doses. Surprisingly, this same U-shaped or J-shaped risk curve has been observed with plain resveratrol. Just 175-350 milligrams of resveratrol reduced the risk of dying from an experimentally-induced heart attack in animals, but 1750 mg increased risk, and 3500 mg human equivalent dose killed the rodent heart every time. Notice that about the same dosage range that is effective in red wine is the safe and effective dose with plain resveratrol.
In a soon-to-be-published study, Longevinex was surprisingly found to exhibit the world’s first L-shaped risk curve — the risk of dying from an intentionally-induced heart attack declined with 100-175 mg of resveratrol in the Longevinex matrix. This same reduced mortality risk was observed at all doses tested (1750 mg, 3500 mg, 7000 mg human-equivalent dose) in laboratory animals. This was demonstrated in two species of animals (mice and rabbits), and over long and short term (30 and 90-days). Understand, this test cannot be duplicated in humans for ethical reasons. This does not give license to take higher doses, but it does speak for safety and lack of cytotoxicity (destruction of living cells). It’s possible mega-dose Longevinex could be safely used for treatment of severe health problems (but this would likely result in it being declared a drug by the FDA). However, it should not be construed that Longevinex has no potential side effects, as anemia from over-consumption is always a possibility. One capsule a day of Longevinex is powerful and remains the recommended dose for healthy adults. -Bill Sardi